sugemalimab   Click here for help

GtoPdb Ligand ID: 12342

Synonyms: Cejemly® (China) | CS-1001 | CS1001 | WBP-3155 | WBP3155
Approved drug
sugemalimab is an approved drug (China (2021))
Compound class: Antibody
Comment: Sugemalimab is a fully human, high-affinity anti-programmed death ligand 1 (PD-L1) IgG4 monoclonal antibody. It is a checkpoint inhibitor class immuno therapeutic. In vitro, it competitively blocks the binding of human PD-L1 to PD-1 and CD80, and it induces T lymphocyte proliferation and enhances antitumour immunity [2].
Classification Click here for help
Compound class Antibody
Ligand families/groups Immune checkpoint modulators
Approved drug? Yes (China (2021))
International Nonproprietary Names Click here for help
INN number INN
11330 sugemalimab
Synonyms Click here for help
Cejemly® (China) | CS-1001 | CS1001 | WBP-3155 | WBP3155
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 1031
Other databases
GtoPdb PubChem SID 479821133
Search PubMed clinical trials sugemalimab
Search PubMed titles sugemalimab
Search PubMed titles/abstracts sugemalimab